Atopic Dermatitis (AD), commonly known as eczema, is one of the most common chronic skin conditions in children. Characterized by persistent dryness, itching, and inflammation, it can significantly affect a child’s comfort, confidence, and daily life. Despite advances in dermatology, many children with moderate to severe AD still struggle to find lasting relief.

At Pediatric Skin Research (PedSkin) in Miami, we are dedicated to improving the future of pediatric dermatology through clinical research. Our team specializes exclusively in clinical trials that focus on developing safer, more effective treatment options for children with skin conditions such as atopic dermatitis.

If your child has moderate to severe eczema, participating in a clinical trial could provide access to cutting-edge therapies not yet available to the public—and contribute to advancements in care for thousands of other children worldwide.

Atopic Dermatitis is a chronic inflammatory condition that leads to dry, red, and intensely itchy skin. It often begins in early childhood and can persist through adolescence. The condition results from a combination of genetic, immune, and environmental factors, which cause a weakened skin barrier and an overactive immune response.

Children with AD may experience flare-ups triggered by irritants, allergens, weather changes, infections, or stress. While not life-threatening, AD can interfere with sleep, concentration, and emotional well-being—impacting both the child and their family.

Common symptoms include:

• Persistent itching and dry, flaky skin
• Red or inflamed patches, especially on the elbows, knees, face, or neck
• Thickened or cracked skin in chronic cases
• Discomfort that may disrupt sleep and school activities

AD affects an estimated 13–25% of children globally, with a slightly higher prevalence among Black children compared to White children. In severe cases, constant itching and visible irritation can cause emotional distress, anxiety, and social withdrawal.

Clinical trials are essential for discovering new treatments and improving quality of life for children living with eczema. At PedSkin Research, our studies are carefully monitored and conducted by board-certified pediatric dermatologists specializing in AD.

Here are a few key benefits for families considering participation:

1. Early Access to New Therapies

Children enrolled in clinical trials may receive investigational treatments—including biologics and JAK inhibitors—before they are widely available. These medications are designed to target specific pathways involved in inflammation, potentially leading to more effective and sustained symptom control.

2. Expert Pediatric Dermatology Care

Each child in our studies is evaluated and monitored by Dr. Mercedes E. Gonzalez, a board-certified pediatric dermatologist and medical director at PedSkin Research. Her team ensures all participants receive compassionate, expert care throughout the study process.

3. Contribution to Medical Advancements

By joining a clinical trial, families contribute to the development of future eczema treatments, helping other children benefit from safer and more effective therapies.

Each study has its own inclusion criteria, but general eligibility for pediatric atopic dermatitis trials includes:

• Age Range: Children between 6 months and 17 years may qualify.
• Diagnosis: Participants must have a confirmed case of moderate to severe AD.
• Extent of Skin Involvement: Some trials require that at least 10% of the body is affected.
• Weight Requirement: For certain medications like Amlitelimab, participants must weigh 25 kg (55 lbs) or more.
• Commitment: Families must be able to attend scheduled visits and follow study protocols during the research period.

These trials are conducted under strict medical supervision to ensure each participant’s safety and comfort.

PedSkin currently offers several active clinical trials for children with mild to severe atopic dermatitis. Each study is designed to evaluate the safety and efficacy of new treatments for pediatric patients.

Each medication targets different immune pathways linked to inflammation, offering the potential for more personalized approaches to treatment.

Systemic (whole-body) therapies are typically recommended for children whose eczema:

• Does not respond adequately to topical treatments
• Causes persistent itching that disrupts sleep or school
• Covers large areas of the body
• Is associated with other allergic conditions, such as asthma or food allergies

Clinical trials at PedSkin are designed for these cases, allowing families to explore new options under professional supervision.

Dr. Mercedes E. Gonzalez, medical director at PedSkin Research, is a board-certified pediatric dermatologist and a leader in pediatric clinical research.

After graduating from Emory University and earning her medical degree from Rutgers–New Jersey Medical School, she completed her pediatrics program at Morgan Stanley Children’s Hospital of New York–Columbia University. She later specialized in dermatology and completed a pediatric dermatology fellowship at New York University (NYU)—one of the top-ranked dermatology programs in the country.

Dr. Gonzalez’s compassionate approach and expertise make her one of the most respected pediatric dermatologists in Miami. She also serves as a clinical assistant professor at FIU and the University of Miami’s Miller School of Medicine, has co-edited three dermatology textbooks, and published over 50 peer-reviewed articles.

If your child is between 6 months and 17 years old and struggling with moderate to severe eczema, they may qualify for one of PedSkin’s active clinical trials.

To learn more, parents can:

• Schedule a consultation with our research team for eligibility screening.
• Attend our upcoming webinar, “New Treatments for Atopic Dermatitis in Children,” which explores the latest studies and treatment options.
• Complete the contact form on our website to request an appointment or learn about future study openings.

All inquiries are confidential and handled by trained staff who guide parents through each step of the process.

• Access to promising new medications before they are FDA-approved
• Comprehensive care from pediatric dermatology specialists
• All treatment costs covered by the study
• Contribution to advancing dermatologic science

Considerations

• Possible side effects are monitored closely by medical professionals
• Each child’s response may vary, and results cannot be guaranteed
• Participation requires time for visits and follow-up evaluations